Induction of cyclo‐oxygenase‐2 by cytokines in human pulmonary epithelial cells: regulation by dexamethasone

British Journal of Pharmacology - Tập 113 Số 3 - Trang 1008-1014 - 1994
Jane A. Mitchell1, Maria G. Belvisi2, Pravit Akarasereenont3, Richard Robbins2, O Jung Kwon2, Jamie J. Croxtall3, Peter J. Barnes2, John R. Vane3
1Department of Applied Pharmacology
2Department of Thoracic Medicine, The National Heart and Lung Institute, Dovehouse Street, London SW3 6LD
3The William Harvey Research Institute, Saint Bartholomew's Hospital Medical College, Charterhouse Square, London EC1M 6BQ

Tóm tắt

Cyclo‐oxygenase metabolizes arachidonic acid to prostaglandin H2 (PGH2) and exists in at least two isoforms. Cyclo‐oxygenase‐1 (COX‐1) is expressed constitutively whereas COX‐2 is induced by lipopolysaccharide (LPS) and some cytokines in vitro and at the site of inflammation in vivo. Epithelial cells may be an important source of prostaglandins in the airways and we have, therefore, investigated the expression of COX‐1 or COX‐2 isoforms in primary cultures of human airway epithelial cells or in a human pulmonary epithelial cell line (A549). COX‐1 or COX‐2 protein was measured by western blot analysis using specific antibodies to COX‐2 and selective antibodies to COX‐1. The activity of COX was assessed by the conversion of either endogenous or exogenous arachidonic acid to four metabolites, PGE2, PGF2α, thromboxane B2 or 6‐oxo PGF1α measured by radioimmunoassay. Thus, COX‐1 or COX‐2 activity was measured under two conditions; initially the accumulation of the COX metabolites formed from endogenous arachidonic acid was measured after 24 h. In other experiments designed to measure COX activity directly, cells were treated with cytokines for 12 h before fresh culture medium was added containing exogenous arachidonic acid (30 μm) for 15min after which COX metabolites were measured. Untreated primary cells or A549 cells contained low amounts of COX‐1 or COX‐2 protein. Bacterial LPS (1 μg ml−1 for 24 h) induced COX‐2 protein in the primary cells, a process which was enhanced by interferon‐γ, with no further increase in the presence of a mixture of cytokines (interleukin‐1β, tumour necrosis factor‐α and interferon‐γ, 10 ng ml−1 for all). In contrast, A549 cells contained only low levels of COX‐2 protein after exposure to LPS or LPS plus interferon‐γ, but contained large amounts of COX‐2 protein after exposure to the mixture of cytokines. Untreated human pulmonary primary cells or A549 cells released low levels of all COX metabolites measured over a 24 h incubation period. This release was enhanced by treatment of either cell type with the mixture of cytokines (interleukin‐10, tumour necrosis factor‐α and interferon‐γ, 10ng ml−1 for all). PGE2 was the principal COX metabolite released by cytokine‐activated epithelial cells. The release of PGE2 induced by cytokines occurred after a lag period of more than 6 h. The glucocorticosteroid, dexamethasone (1 μm; 30 min prior to cytokines) completely suppressed the cytokine‐induced expression of COX‐2 protein and activity in both primary cells and A549 cells. In experiments where COX‐2 activity was supported by endogenous stores of arachidonic acid, treatment of A549 cells with interleukin‐10 but not tumour necrosis factor‐α or interferon‐γ alone caused a similar release of PGE2 to that seen when the cytokines were given in combination. However, both interleukin‐10 and necrosis factor‐α alone produced similar increases in COX‐2 activity (measured in the presence of exogenous arachidonic acid) as seen when the mixture of interleukin‐1β, tumour necrosis factor‐α and interferon‐γ were used to stimulate the cells. These findings show that COX‐2 expression correlates with the exaggerated release of prostaglandins from cytokine‐activated human pulmonary epithelial cells and that the induction of the enzyme is suppressed by a glucocorticosteroid. These findings may be relevant to inflammatory diseases of the lung, such as asthma.

Từ khóa


Tài liệu tham khảo

AKARASEREENONT P., 1994, Lipopolysaccharide induces bovine aortic endothelial cells to synthesize COX, but not nitric oxide synthase: a comparison with macrophages, Br. J. Pharmacol., 111, 33P

10.1111/j.1476-5381.1985.tb09434.x

BARNES P.J., 1994, Airway epithelial receptors, Eur. Resp. J.

10.1164/ajrccm/148.4_Pt_2.S1

10.1164/ajrccm/140.1.137

10.1164/ajrccm/140.2.449

10.1073/pnas.89.8.3571

10.1002/ijc.2910540124

10.1038/262699a0

10.1016/0014-2999(89)90451-2

10.1073/pnas.85.24.9797

10.1016/0954-6111(93)90064-7

10.1016/0165-6147(93)90071-Q

10.1073/pnas.71.9.3400

10.1172/JCI116971

10.1073/pnas.89.16.7384

10.1164/ajrccm/148.6_Pt_1.1447

KUJUBU D.A., 1991, TIS10, a phorbol ester tumor pro‐moter‐inducible mRNA from swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclo‐oxyenase homologue, J. Biol. Chem., 266, 12866, 10.1016/S0021-9258(18)98774-0

KWON O.J., 1994, Inhibition of interleukin‐8 expression by dexamethasone in human cultured epithelial cells, Immunology, 81, 389

KWON O.J., 1994, Glucocorticoid inhibition of TNFα‐induced interleukin‐8 expression in primary cultured human airway epithelial cells, Am. J. Physiol.

LEE S.H., 1992, Selective expression of mitogen‐inducible cyclo‐oxygenase in macrophages stimulated with lipopolysaccharide, J. Biol. Chem., 267, 25934, 10.1016/S0021-9258(18)35698-9

LIN L.‐L., 1992, Inhibition of phospholipase A2 expression by dexamethasone, J. Biol. Chem., 267, 23451

MAIER J.A., 1990, Cyclo‐oxygenase is an immediate early gene induced by interleukin‐1 in human endothelial cells, J. Biol. Chem., 265, 10805, 10.1016/S0021-9258(19)38515-1

10.1172/JCI110207

10.1172/JCI114850

10.1016/S0021-9258(18)53294-4

10.1073/pnas.90.24.11693

MITCHELL J.A., 1994, Induction of cyclo‐oxygenase‐2 in human pulmonary epithelial cells, Br. J. Pharmacol., 112, 78P

MITCHELL J.A., 1992, Induction of NADPH‐dependent diaphorase and nitric oxide synthase activity in aortic smooth muscle and cultured macrophages, Mol. Pharmacol., 104, 189

MITCHELL J.A., 1993, Regulation of prostacyclin synthesis by endogenous nitric oxide in response to bacterial lipopolysaccharide, Br. J. Pharmacol., 109, 4P

MONICK M., 1987, Human alveolar macrophages suppress interleukin‐1 (IL‐1) activity via the secretion of prostaglandin E2, Am. Rev. Respir. Dis., 135, 72

NEIL G.P., 1993, Expression of mRNA for cyclo‐oxygenase‐1 and cyclo‐oxygenase‐2 in human tissue, FEBS, 330, 156

10.1073/pnas.89.11.4888

10.1111/j.1749-6632.1971.tb53205.x

10.1073/pnas.87.24.10043

10.1016/S0006-291X(05)80068-3

10.1378/chest.83.5_Supplement.92S

10.1006/bbrc.1994.1119

SALMON J.A., 1978, A radioimmunoassay for 6‐keto‐prostaglan‐dins F1ot, Prostaglandins, 5, 383

SELDON P.M., 1994, Phosphodiesterase IV inhibitors and β‐adrenoceptor agonists suppress lipopolysaccharide‐induced tumour necrosis factor‐α generation by human peripheral blood monocytes, Br. J. Pharmacol., 112, 215P

10.1097/00041433-199310000-00009

10.1038/newbio231232a0

10.1038/367215a0

10.1073/pnas.91.6.2046

10.1073/pnas.88.7.2692

Thông tin
Thông tin xuất bản

British Journal of Pharmacology

Tập 113 Số 3

1008-1014

Thông tin tác giả